IL88531A - Cognitive enhancing compositions containing d-cycloserine - Google Patents

Cognitive enhancing compositions containing d-cycloserine

Info

Publication number
IL88531A
IL88531A IL88531A IL8853188A IL88531A IL 88531 A IL88531 A IL 88531A IL 88531 A IL88531 A IL 88531A IL 8853188 A IL8853188 A IL 8853188A IL 88531 A IL88531 A IL 88531A
Authority
IL
Israel
Prior art keywords
cycloserine
compositions containing
enhancing compositions
cognitive enhancing
cognitive
Prior art date
Application number
IL88531A
Other languages
English (en)
Other versions
IL88531A0 (en
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Publication of IL88531A0 publication Critical patent/IL88531A0/xx
Publication of IL88531A publication Critical patent/IL88531A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL88531A 1987-12-01 1988-11-29 Cognitive enhancing compositions containing d-cycloserine IL88531A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/127,121 US4904681A (en) 1987-12-01 1987-12-01 D-cycloserine and its prodrugs as cognitive enhancers

Publications (2)

Publication Number Publication Date
IL88531A0 IL88531A0 (en) 1989-06-30
IL88531A true IL88531A (en) 1993-02-21

Family

ID=22428413

Family Applications (1)

Application Number Title Priority Date Filing Date
IL88531A IL88531A (en) 1987-12-01 1988-11-29 Cognitive enhancing compositions containing d-cycloserine

Country Status (20)

Country Link
US (1) US4904681A (cg-RX-API-DMAC10.html)
EP (2) EP0319824B1 (cg-RX-API-DMAC10.html)
JP (2) JPH0621065B2 (cg-RX-API-DMAC10.html)
KR (1) KR0134198B1 (cg-RX-API-DMAC10.html)
AT (1) ATE68698T1 (cg-RX-API-DMAC10.html)
AU (4) AU622630B2 (cg-RX-API-DMAC10.html)
CA (1) CA1328617C (cg-RX-API-DMAC10.html)
DE (1) DE3865817D1 (cg-RX-API-DMAC10.html)
DK (1) DK173589B1 (cg-RX-API-DMAC10.html)
ES (1) ES2040314T3 (cg-RX-API-DMAC10.html)
FI (1) FI885559A0 (cg-RX-API-DMAC10.html)
GR (1) GR3003571T3 (cg-RX-API-DMAC10.html)
IE (1) IE61825B1 (cg-RX-API-DMAC10.html)
IL (1) IL88531A (cg-RX-API-DMAC10.html)
NO (1) NO885337D0 (cg-RX-API-DMAC10.html)
NZ (1) NZ227131A (cg-RX-API-DMAC10.html)
PH (1) PH26467A (cg-RX-API-DMAC10.html)
PT (1) PT89109B (cg-RX-API-DMAC10.html)
WO (1) WO1989005144A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA888981B (cg-RX-API-DMAC10.html)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5187171A (en) * 1989-01-09 1993-02-16 G. D. Searle & Co. Use of a glycine b partial agonist as an antipsychotic
US5061721A (en) * 1989-03-15 1991-10-29 G. D. Searle & Co. Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US5260324A (en) * 1990-02-06 1993-11-09 G. D. Searle & Company Composition containing D-cycloserine and D-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US5066665A (en) * 1990-05-21 1991-11-19 Warner-Lambert Co. Substituted isoxazolidin-3-ones and derivatives thereof acting at muscarinic receptors
JPH07505908A (ja) * 1992-09-28 1995-06-29 マックセチーニ、マリア　ルイザ Ｎｍｄａ受容体のアロステリックモジュレーター
US5428069A (en) * 1993-01-11 1995-06-27 The United States Of America As Represented By The Department Of Health & Human Services Treating cognition with, aminocyclopropanecarboxylic derivatives
US5523323A (en) * 1993-09-14 1996-06-04 Maccecchini; Maria-Luisa Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence
NZ260302A (en) * 1994-04-13 1996-05-28 New Zealand Meat Ind Res Inst Treating bait aversion by including substances which disrupt the associative learning process into bait compositions
AU4128896A (en) * 1994-11-23 1996-06-17 G.D. Searle & Co. Use of amino-isoxazolidone compounds for treatment of memory impairment following traumatic brain injury
AU4019395A (en) 1994-11-23 1996-06-17 G.D. Searle & Co. Use of amino-isoxazolidone compounds for improvement of implicit memory
JPH11501619A (ja) * 1995-02-15 1999-02-09 ベアーズデン バイオ，インコーポレイテッド アルキルカルボキシアミノ酸−カイネートレセプターのモジュレーター
US6355681B2 (en) * 1995-12-07 2002-03-12 Glytech, Inc. Glycine substitutes and precursors for treating a psychosis
EP0871440B1 (en) * 1995-12-07 2006-03-22 Daniel C. Javitt Treatment of negative and cognitive symptoms of schizophrenia with glycine uptake antagonists
US6361957B1 (en) 1999-08-03 2002-03-26 Glytech, Inc. Assay for D-serine transport antagonist and use for treating psychosis
FR2742748B1 (fr) * 1995-12-21 1998-01-30 Adir Nouveau derive de 4-imidazolidinone, son procede de preparation et les compositions pharmaceutiques qui le contiennent
KR100396114B1 (ko) * 1996-10-31 2003-11-20 동아제약 주식회사 D-시클로세린의 제조방법
JP2002511409A (ja) 1998-04-14 2002-04-16 ザ ジュネラル ホスピタル コーポレーション 神経精神疾患の治療法
EP1084704B1 (en) * 1998-06-10 2006-03-29 Meiji Seika Kaisha Ltd. Remedies for spinocerebellar ataxia and compositions for treating spinocerebellar ataxia
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
US7750030B2 (en) * 2001-03-29 2010-07-06 Michael Davis Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
US20060252761A1 (en) * 2001-03-29 2006-11-09 Michael Davis Augmentation of extinction via administration of sub-antimicrobial doses of D-cycloserine
WO2002078615A2 (en) 2001-04-02 2002-10-10 Panorama Research, Inc. Antioxidant nitroxides and nitrones as therapeutic agents
US7160913B2 (en) * 2002-09-13 2007-01-09 Thomas Jefferson University Methods and kit for treating Parkinson's disease
KR20070104480A (ko) * 2003-05-27 2007-10-25 포레스트 래보러토리즈, 인코포레이티드 우울증 및 그 밖의 기분장애의 치료를 위한 ｎｍｄａ수용체 길항제 및 선택적 세로토닌 재흡수 억제제의 배합물
CA2534909A1 (en) * 2003-08-08 2005-02-17 The Burnham Institute P16 mediated regulation of nmda receptors
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
JP5666087B2 (ja) 2005-04-06 2015-02-12 アダマス・ファーマシューティカルズ・インコーポレーテッド Ｃｎｓ関連疾患の治療のための方法及び組成物
CN102186883B (zh) 2008-09-18 2016-08-03 西北大学 Nmda受体调节剂和其用途
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
WO2011100585A1 (en) 2010-02-11 2011-08-18 Joseph Moskal Secondary structure stabilized nmda receptor modulators and uses thereof
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
CN105026401A (zh) 2013-01-29 2015-11-04 诺雷克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
PE20151436A1 (es) 2013-01-29 2015-10-10 Naurex Inc Moduladores de receptores nmda de espiro-lactama y sus usos
US9828384B2 (en) 2013-01-29 2017-11-28 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
BR112015018092A2 (pt) 2013-01-29 2017-07-18 Naurex Inc moduladores de receptor de nmda de espiro-lactama e usos dos mesmos
BR112015018087B1 (pt) 2013-01-29 2022-09-20 Aptinyx Inc Compostos moduladores de receptor n-metil-d-aspartato (nmda) de espiro-lactama, composição farmacêutica e uso dos mesmos
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
CN109415372B (zh) 2016-05-19 2021-01-15 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
JP2019527235A (ja) 2016-08-01 2019-09-26 アプティニックス インコーポレイテッド スピロ−ラクタム及びビス−スピロ−ラクタムｎｍｄａ受容体修飾因子及びその使用
ES2972533T3 (es) 2016-08-01 2024-06-13 Tenacia Biotechnology Hong Kong Co Ltd Moduladores del receptor de NMDA a base de espirolactama, y sus usos
CN109843889B (zh) 2016-08-01 2022-03-15 阿普廷伊克斯股份有限公司 螺-内酰胺nmda调节剂和使用其的方法
CN109937204B (zh) 2016-08-01 2022-11-25 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
CA3031539C (en) 2016-08-01 2023-11-28 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
EP3427729A1 (en) 2017-07-13 2019-01-16 Paris Sciences et Lettres - Quartier Latin Probenecid for use in treating epileptic diseases, disorders or conditions
KR102761196B1 (ko) 2018-01-31 2025-02-03 테나시아 바이오테크놀로지 (홍콩) 코., 리미티드 스피로-락탐 nmda 수용체 조정제 및 그의 용도
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3050800C2 (cg-RX-API-DMAC10.html) * 1979-03-22 1989-06-22 Continental Pharma Inc., Bruessel/Bruxelles, Be

Also Published As

Publication number Publication date
EP0319824A1 (en) 1989-06-14
NO885337D0 (no) 1988-11-30
AU2631988A (en) 1989-06-01
PT89109A (pt) 1989-12-29
JPH0621065B2 (ja) 1994-03-23
PH26467A (en) 1992-07-27
GR3003571T3 (cg-RX-API-DMAC10.html) 1993-03-16
AU2813089A (en) 1989-07-05
EP0319824B1 (en) 1991-10-23
AU7746794A (en) 1995-01-05
AU622630B2 (en) 1992-04-16
DE3865817D1 (cg-RX-API-DMAC10.html) 1991-11-28
WO1989005144A1 (en) 1989-06-15
IE883567L (en) 1989-06-01
CA1328617C (en) 1994-04-19
ES2040314T3 (es) 1995-04-01
DK669088D0 (da) 1988-11-30
AU1083992A (en) 1992-05-07
IE61825B1 (en) 1994-11-30
ATE68698T1 (de) 1991-11-15
FI885559A0 (fi) 1988-11-30
KR890009392A (ko) 1989-08-01
ZA888981B (en) 1990-01-31
DK669088A (da) 1989-06-02
KR0134198B1 (ko) 1998-04-21
JPH01193220A (ja) 1989-08-03
IL88531A0 (en) 1989-06-30
JPH05201859A (ja) 1993-08-10
DK173589B1 (da) 2001-04-02
PT89109B (pt) 1993-07-30
US4904681A (en) 1990-02-27
EP0421997A1 (en) 1991-04-17
NZ227131A (en) 1991-09-25

Similar Documents

Publication Publication Date Title
IL88531A (en) Cognitive enhancing compositions containing d-cycloserine
TW218869B (cg-RX-API-DMAC10.html)
DE3779053D1 (cg-RX-API-DMAC10.html)
EP0563345A4 (en) Novel 4-arylpiperazines and 4-arylpiperidines
EG18729A (en) Compound of n- amino - 1,2,4-triazinones used as insecticide.
IL128425A0 (en) Taxane derivatives their preparation and pharmaceutical compositions containing them
GR3007513T3 (cg-RX-API-DMAC10.html)
ZA933496B (en) New 7betabsubstituted-4-aza-5alpha-cholestan-3-ones as 5alpha-reductase inhibitors
ES8704931A1 (es) Un procedimiento para la preparacion de derivados de piridimilmidazolidiona.
NO174807C (cg-RX-API-DMAC10.html)
GB8728675D0 (en) Compounds & compositions
GR3004959T3 (cg-RX-API-DMAC10.html)
ZA888726B (en) Tert-butyl phenyl compounds useful as anti-inflammatory agents
ZA88498B (en) Alkylmelatonins
IL71989A (en) L-arginine isoxicamate and pharmaceutical compositions containing it
GB8704839D0 (en) Compound compositions
IL65120A (en) Herbicidal thiocarbamate compositions containing 2,4-dinitrophenol as antidote thereto
UA19097A (uk) D-1-ФЕHІЛ-2-МЕТИЛАМІHОПРОПАHОЛА 1-5,6,7-ТРИОКСИФЛАВОH-7-0-beta-D-ГЛЮКУРОHИДАТ, ЩО МАЄ ОКИСЛЮВАЛЬHУ ДІЮ ТА РОЗШИРЮЄ СУДИHИ
AU662224B2 (en) New 7beta-substituted-4-aza-5alpha-androstan-3-ones as 5alpha-reductase inhibitors
DK1260222T3 (da) Farmaceutiske præparater indeholdende hidtil ukendte iso-butenyl-substituerede taxaner
IE851753L (en) Aminophenol compounds.

Legal Events

Date Code Title Description
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees